

# Hirotsugu Kenmotsu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7463723/publications.pdf>

Version: 2024-02-01

51  
papers

1,636  
citations

331538

21  
h-index

302012

39  
g-index

52  
all docs

52  
docs citations

52  
times ranked

2438  
citing authors

#	ARTICLE	IF	CITATIONS
1	Predictive value of EGFR mutation in non-small cell lung cancer patients treated with platinum doublet postoperative chemotherapy. <i>Cancer Science</i> , 2022, 113, 287-296.	1.7	10
2	Long-term survival data of patients with limited disease small cell lung cancer: a retrospective analysis. <i>Investigational New Drugs</i> , 2022, 40, 411-419.	1.2	5
3	Nintedanib plus chemotherapy for nonsmall cell lung cancer with idiopathic pulmonary fibrosis: a randomised phase 3 trial. <i>European Respiratory Journal</i> , 2022, 60, 2200380.	3.1	34
4	Predicting the efficacy of first-line immunotherapy by combining cancer cachexia and tumor burden in advanced non-small cell lung cancer. <i>Thoracic Cancer</i> , 2022, 13, 2064-2074.	0.8	7
5	Proposing synchronous oligometastatic non-small cell lung cancer based on progression after first-line systemic therapy. <i>Cancer Science</i> , 2021, 112, 359-368.	1.7	10
6	Unfavorable impact of decreased muscle quality on the efficacy of immunotherapy for advanced non-small cell lung cancer. <i>Cancer Medicine</i> , 2021, 10, 247-256.	1.3	20
7	Tumor mutation burden as a biomarker for lung cancer patients treated with pemetrexed and cisplatin (the JIPANGATEL). <i>Cancer Science</i> , 2021, 112, 388-396.	1.7	16
8	Cumulative incidence of venous thromboembolism in patients with advanced cancer in prospective observational study. <i>Cancer Medicine</i> , 2021, 10, 895-904.	1.3	16
9	Radiographic features and poor prognostic factors of interstitial lung disease with nivolumab for non-small cell lung cancer. <i>Cancer Science</i> , 2021, 112, 1495-1505.	1.7	8
10	Treatment and relapse of interstitial lung disease in nivolumab-treated patients with non-small cell lung cancer. <i>Cancer Science</i> , 2021, 112, 1506-1513.	1.7	14
11	Phase 1 study of telisotuzumab vedotin in Japanese patients with advanced solid tumors. <i>Cancer Medicine</i> , 2021, 10, 2350-2358.	1.3	5
12	Reply to J. L. Derks et al. <i>Journal of Clinical Oncology</i> , 2021, 39, 1509-1510.	0.8	0
13	Re: Immune checkpoint blockade for patients with lung cancer and idiopathic pulmonary fibrosis. <i>European Journal of Cancer</i> , 2021, 151, 249-251.	1.3	1
14	Rechallenge with previously administered epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer with leptomeningeal metastasis. <i>Investigational New Drugs</i> , 2021, 39, 1732-1741.	1.2	2
15	Current Treatment Strategies for Non-Small-Cell Lung Cancer with Comorbid Interstitial Pneumonia. <i>Cancers</i> , 2021, 13, 3979.	1.7	7
16	Impact of angiogenesis inhibitor eligibility on the prognosis of patients with non-small cell lung cancer harboring EGFR mutation. <i>Cancer Medicine</i> , 2021, 10, 7503-7513.	1.3	4
17	Phase II study of multidisciplinary therapy combined with pembrolizumab for patients with synchronous oligometastatic non-small cell lung cancer TRAP OLIGO study (WJOG11118L). <i>BMC Cancer</i> , 2021, 21, 1121.	1.1	3
18	Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study. <i>BMC Cancer</i> , 2021, 21, 1247.	1.1	3

#	ARTICLE	IF	CITATIONS
19	A Phase 2 Study of Atezolizumab for Pretreated NSCLC With Idiopathic Interstitial Pneumonitis. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1935-1942.	0.5	50
20	Randomized Phase III Study of Irinotecan Plus Cisplatin Versus Etoposide Plus Cisplatin for Completely Resected High-Grade Neuroendocrine Carcinoma of the Lung: JCOG1205/1206. <i>Journal of Clinical Oncology</i> , 2020, 38, 4292-4301.	0.8	26
21	Randomized Phase III Study of Pemetrexed Plus Cisplatin Versus Vinorelbine Plus Cisplatin for Completely Resected Stage II to IIIA Nonsquamous Non-small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 2187-2196.	0.8	78
22	Association Between Clinical Tumor Burden and Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non-small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2020, 21, e405-e414.	1.1	21
23	Evaluation of gefitinib systemic exposure in EGFR-mutated non-small cell lung cancer patients with gefitinib-induced severe hepatotoxicity. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 605-614.	1.1	3
24	Desensitizing Effect of Cancer Cachexia on Immune Checkpoint Inhibitors in Patients With Advanced NSCLC. <i>JTO Clinical and Research Reports</i> , 2020, 1, 100020.	0.6	23
25	Summary of the Japanese Respiratory Society statement for the treatment of lung cancer with comorbid interstitial pneumonia. <i>Respiratory Investigation</i> , 2019, 57, 512-533.	0.9	36
26	Phase II study of nab-paclitaxel plus carboplatin for patients with non-small-cell lung cancer and interstitial lung disease. <i>Cancer Science</i> , 2019, 110, 3738-3745.	1.7	49
27	Radiologic features of pneumonitis associated with nivolumab in non-small-cell lung cancer and malignant melanoma. <i>Future Oncology</i> , 2019, 15, 1911-1920.	1.1	36
28	Genetic alterations of driver genes as independent prognostic factors for disease-free survival in patients with resected non-small cell lung cancer. <i>Lung Cancer</i> , 2019, 128, 152-157.	0.9	12
29	Palliative cerebrospinal fluid shunting for leptomeningeal metastasis-related hydrocephalus in patients with lung adenocarcinoma: A single-center retrospective study. <i>PLoS ONE</i> , 2019, 14, e0210074.	1.1	19
30	ILD-NSCLC-GAP index scoring and staging system for patients with non-small cell lung cancer and interstitial lung disease. <i>Lung Cancer</i> , 2018, 121, 48-53.	0.9	15
31	Treatment Rationale and Design for J-SONIC: A Randomized Study of Carboplatin Plus Nab-paclitaxel With or Without Nintedanib for Advanced Non-small-cell Lung Cancer With Idiopathic Pulmonary Fibrosis. <i>Clinical Lung Cancer</i> , 2018, 19, e5-e9.	1.1	44
32	Randomized Phase III Study of Cisplatin With Pemetrexed and Cisplatin With Vinorelbine for Completely Resected Nonsquamous Non-small-Cell Lung Cancer: The JIPANG Study Protocol. <i>Clinical Lung Cancer</i> , 2018, 19, e1-e3.	1.1	16
33	Clinical Factors Predicting Detection of T790M Mutation in Rebiopsy for EGFR-Mutant Non-small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2018, 19, e247-e252.	1.1	41
34	Isolation and molecular analysis of circulating tumor cells from lung cancer patients using a microfluidic chip type cell sorter. <i>Cancer Science</i> , 2018, 109, 2539-2548.	1.7	35
35	Successful osimertinib rechallenge in a patient with advanced non-small cell lung cancer following osimertinib-induced interstitial lung disease after treatment with nivolumab. <i>Investigational New Drugs</i> , 2017, 35, 839-841.	1.2	10
36	The incidence and risk factors of febrile neutropenia in chemotherapy-naïve lung cancer patients receiving etoposide plus platinum. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 1229-1237.	1.1	13

#	ARTICLE	IF	CITATIONS
37	Modified <sc>GAP</sc> index for prediction of acute exacerbation of idiopathic pulmonary fibrosis in non-small cell lung cancer. <i>Respirology</i> , 2017, 22, 1379-1385.	1.3	20
38	The effects of advanced age and serum Î± <sub>1</sub> -acid glycoprotein on docetaxel unbound exposure and dose-limiting toxicity in cancer patients. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 2416-2425.	1.1	14
39	Osimertinib-induced interstitial lung disease after treatment with anti-PD1 antibody. <i>Investigational New Drugs</i> , 2017, 35, 105-107.	1.2	45
40	Nivolumab-induced interstitial lung disease (ILD) in Japanese patients with non-small cell lung cancer: A study on risk factors using interim results of post-marketing all-case surveillance. <i>Journal of Clinical Oncology</i> , 2017, 35, 9078-9078.	0.8	10
41	Pharmacokinetics, dynamics and toxicity of docetaxel: Why the Japanese dose differs from the Western dose. <i>Cancer Science</i> , 2015, 106, 497-504.	1.7	123
42	Effect of platinum-based chemotherapy for non-small cell lung cancer patients with interstitial lung disease. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 521-526.	1.1	62
43	Efficacy and Safety of Combined Carboplatin, Paclitaxel, and Bevacizumab for Patients with Advanced Non-squamous Non-small Cell Lung Cancer with Pre-existing Interstitial Lung Disease: A Retrospective Multi-institutional Study. <i>Anticancer Research</i> , 2015, 35, 4259-63.	0.5	30
44	A Phase III Trial Comparing Irinotecan and Cisplatin with Etoposide and Cisplatin in Adjuvant Chemotherapy for Completely Resected Pulmonary High-grade Neuroendocrine Carcinoma (JCOG1205/1206). <i>Japanese Journal of Clinical Oncology</i> , 2014, 44, 379-382.	0.6	23
45	Progression-free survival at 2 years is a reliable surrogate marker for the 5-year survival rate in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy. <i>BMC Cancer</i> , 2014, 14, 18.	1.1	27
46	Assessment of mutational profile of Japanese lung adenocarcinoma patients by multitarget assays: A prospective, single-institute study. <i>Cancer</i> , 2014, 120, 1471-1481.	2.0	65
47	A pilot study of adjuvant chemotherapy with irinotecan and cisplatin for completely resected high-grade pulmonary neuroendocrine carcinoma (large cell neuroendocrine carcinoma and small cell neuroendocrine carcinoma). <i>Journal of Thoracic Oncology</i> , 2014, 9, 1471-1481.	1.0	14
48	Size-Based Isolation of Circulating Tumor Cells in Lung Cancer Patients Using a Microcavity Array System. <i>PLoS ONE</i> , 2013, 8, e67466.	1.1	151
49	Prognostic Impact of Circulating Tumor Cells in Patients with Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2012, 7, 512-519.	0.5	166
50	The Risk of Cytotoxic Chemotherapy-Related Exacerbation of Interstitial Lung Disease with Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2011, 6, 1242-1246.	0.5	177
51	Clinical impact of tumour burden on the efficacy of <sc>PD</sc> inhibitors plus chemotherapy in non-small cell lung cancer. <i>Cancer Medicine</i> , 0, , .	1.3	1